Tags

Type your tag names separated by a space and hit enter

Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones.
Int J Antimicrob Agents. 2005 Oct; 26(4):323-6.IJ

Abstract

In a database cohort study, the risk of adverse birth outcome in Danish women who redeemed a fluoroquinolone prescription during pregnancy was examined. Among 87 women who redeemed a fluoroquinolone prescription at any time during the pregnancy, the prevalence ratio of preterm birth was 1.4 (95% confidence interval (CI), 0.6-3.2), one woman had a stillbirth, and no children died during the perinatal period. Among 130 women who redeemed a prescription during the first trimester or 30 days before conception, the prevalence ratio of congenital malformation was 0.7 (95% CI, 0.3-2.0) and the prevalence ratio of bone malformations was 2.2 (95% CI, 0.7-6.7). Our study raises the concern that prenatal fluoroquinolone exposure may be associated with an increased risk of bone malformations.

Authors+Show Affiliations

Department of Clinical Epidemiology, Aarhus University Hospital, Aalborg, Denmark. aas.uxpiwo@nja.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16144758

Citation

Wogelius, Pia, et al. "Further Analysis of the Risk of Adverse Birth Outcome After Maternal Use of Fluoroquinolones." International Journal of Antimicrobial Agents, vol. 26, no. 4, 2005, pp. 323-6.
Wogelius P, Nørgaard M, Gislum M, et al. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. Int J Antimicrob Agents. 2005;26(4):323-6.
Wogelius, P., Nørgaard, M., Gislum, M., Pedersen, L., Schønheyder, H. C., & Sørensen, H. T. (2005). Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. International Journal of Antimicrobial Agents, 26(4), 323-6.
Wogelius P, et al. Further Analysis of the Risk of Adverse Birth Outcome After Maternal Use of Fluoroquinolones. Int J Antimicrob Agents. 2005;26(4):323-6. PubMed PMID: 16144758.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. AU - Wogelius,Pia, AU - Nørgaard,Mette, AU - Gislum,Mette, AU - Pedersen,Lars, AU - Schønheyder,Henrik C, AU - Sørensen,Henrik Toft, PY - 2005/05/23/received PY - 2005/06/03/accepted PY - 2005/9/8/pubmed PY - 2006/1/4/medline PY - 2005/9/8/entrez SP - 323 EP - 6 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 26 IS - 4 N2 - In a database cohort study, the risk of adverse birth outcome in Danish women who redeemed a fluoroquinolone prescription during pregnancy was examined. Among 87 women who redeemed a fluoroquinolone prescription at any time during the pregnancy, the prevalence ratio of preterm birth was 1.4 (95% confidence interval (CI), 0.6-3.2), one woman had a stillbirth, and no children died during the perinatal period. Among 130 women who redeemed a prescription during the first trimester or 30 days before conception, the prevalence ratio of congenital malformation was 0.7 (95% CI, 0.3-2.0) and the prevalence ratio of bone malformations was 2.2 (95% CI, 0.7-6.7). Our study raises the concern that prenatal fluoroquinolone exposure may be associated with an increased risk of bone malformations. SN - 0924-8579 UR - https://www.unboundmedicine.com/medline/citation/16144758/Further_analysis_of_the_risk_of_adverse_birth_outcome_after_maternal_use_of_fluoroquinolones_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(05)00195-0 DB - PRIME DP - Unbound Medicine ER -